--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------
07.06.2011
MORRISVILLE, NC, June 7, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss
Exchange: OXBT) today announced it has received approval to conduct its
traumatic brain injury Phase IIb clinical trials known as STOP-TBI in India by
the Drug Controller General of India. Oxygen Biotherapeutics believes the
addition of India to its existing clinical sites in Switzerland and Israel will
enable the Company to conclude the study faster and more economically. The next
cohort is expected to begin in the second half of fiscal year 2012.
"We are pleased that we received this approval and look forward to working with
our new clinical sites," said Chris Stern, Chairman and Chief Executive Officer
of Oxygen Biotherapeutics. "Currently, we are amending the protocol to include
patients with milder forms of TBI, and we are developing the processes for
manufacturing cGMP Oxycyte PFC for the study. In addition, we are seeking a
partner to help us execute the remaining aspects of this trial because we
believe that makes strategic sense and is in the best interest of our
shareholders."
The STOP-TBI study is a double-blind, placebo controlled dose-escalation study
designed to evaluate the safety, efficacy and dosing parameters of Oxycyte PFC,
a novel perfluorocarbon emulsion that is given intravenously to traumatic brain
injury patients. The study´s first cohort has been completed and the database
has been locked.
end of ad-hoc-announcement
================================================================================
About Oxygen Biotherapeutics, Inc.
Headquartered in Morrisville, NC, Oxygen Biotherapeutics, Inc. is developing
medical and cosmetic products that efficiently deliver oxygen to tissues in the
body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic
oxygen carrier that is being formulated for both intravenous and topical
delivery. This year, the company launched its DERMACYTE® line of oxygen-rich
skin care products. In addition, the company is focused on perfluorocarbon-based
oxygen carriers for use in traumatic brain injury, decompression sickness,
personal care, dermatology and topical wound healing. More information is
available at www.oxybiomed.com or www.dermacyteus.com.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company's judgment as of
the date of this release. These statements include the management transition,
and expansion of research and development of the Oxycyte product line, including
and the timing of the introduction of those new products. The forward-looking
statements are subject to a number of risks and uncertainties including matters
beyond the company’s control that could lead to delays in new product
introductions and customer acceptance of these new products, and other risks and
uncertainties as described in our filings with the Securities and Exchange
Commission, including in the current report on Form 10-Q filed on September 9,
2010. The company disclaims any intent or obligation to update these
forward-looking statements beyond the date of this release. This caution is made
under the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Further inquiry note:
Ellen Corliss
Vice President, Corporate Communications
& Investor Relations
Oxygen Biotherapeutics, Inc
One Copley Parkway, Suite 490
Morrisville, NC 27560
Direct Telephone: +1 919 855 2112
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: Oxygen Biotherapeutics Inc.
2530 Meridian Pkwy
US-27713 Durham, NC
phone: +1(919)7607606
FAX: +1(419)7108764
mail: c.stern@oxybiomed.com
WWW: www.oxybiomed.com
sector: Biotechnology
ISIN: US69207P2092
indexes: SSIRT
stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange
language: English
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | EAE
